Grant: Canada Postdoctoral Research Award (CPRA) program
Direct Payment
$140,000.00
Optimizing the Safety and Effectiveness of Cannabinoid Therapies: Cannabidiol, Cannabigerol, and Cannabichromene as Modulators of Delta-9-Tetrahydrocannabinol's Analgesic and Adverse Effects
EF 2025-26
Résumé
Pain is the most common reason people seek healthcare and approximately 20% of North Americans live with chronic pain. Opioid medications are often used for pain management but can be harmful when misused, creating the need for safer alternative treatments. Medical cannabis is being increasingly prescribed to alleviate pain, but one of its primary compounds, delta-9-tetrahydrocannabinol (THC), also causes intoxication, cognitive impairments, and carries a risk of misuse, limiting its clinical potential.
There are other compounds in cannabis, including cannabidiol (CBD), cannabigerol (CBG), and cannabichromene (CBC), which hold promise for pain relief. Studies in animals indicate that these cannabinoids elicit analgesic effects without the prototypical adverse effects observed with THC. These compounds may also reduce the intoxicating effects of THC while enhancing its pain-relieving effects. However, it is unclear whether these THC-sparing effects extend to humans. This study will determine whether CBD, CBG, and CBC can reduce THC's adverse effects, including cognitive disruption and intoxication, and enhance its pain-relieving properties.
We will give men and women different combinations of THC, CBD, CBG, and CBC in a controlled setting at different dose levels and will measure pain sensitivity, mood, cognitive effects, subjective drug effects, and intoxication levels. Ultimately, this research will clarify whether these cannabinoids can be used to make cannabis-based treatments safer and more effective, thereby leading to new and improved ways to help people living with pain.
Programme
Canada Postdoctoral Research Award (CPRA) program
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
537110
Name
Sorkhou Maryam
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Canada Postdoctoral Research Award - B
Projecttitle
Optimizing the Safety and Effectiveness of Cannabinoid Therapies: Cannabidiol, Cannabigerol, and Cannabichromene as Modulators of Delta-9-Tetrahydrocannabinol's Analgesic and Adverse Effects
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Analgesia; Appetite; Cannabichromene; Cannabidiol; Cannabigerol; Cannabinoids; Mood; Pain; Sex Differences
Abstract
Pain is the most common reason people seek healthcare and approximately 20% of North Americans live with chronic pain. Opioid medications are often used for pain management but can be harmful when misused, creating the need for safer alternative treatments. Medical cannabis is being increasingly prescribed to alleviate pain, but one of its primary compounds, delta-9-tetrahydrocannabinol (THC), also causes intoxication, cognitive impairments, and carries a risk of misuse, limiting its clinical potential.
There are other compounds in cannabis, including cannabidiol (CBD), cannabigerol (CBG), and cannabichromene (CBC), which hold promise for pain relief. Studies in animals indicate that these cannabinoids elicit analgesic effects without the prototypical adverse effects observed with THC. These compounds may also reduce the intoxicating effects of THC while enhancing its pain-relieving effects. However, it is unclear whether these THC-sparing effects extend to humans. This study will determine whether CBD, CBG, and CBC can reduce THC's adverse effects, including cognitive disruption and intoxication, and enhance its pain-relieving properties.
We will give men and women different combinations of THC, CBD, CBG, and CBC in a controlled setting at different dose levels and will measure pain sensitivity, mood, cognitive effects, subjective drug effects, and intoxication levels. Ultimately, this research will clarify whether these cannabinoids can be used to make cannabis-based treatments safer and more effective, thereby leading to new and improved ways to help people living with pain.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Sorkhou, Maryam
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~